Research programme: cyclocreatine - Lumos Pharma

Drug Profile

Research programme: cyclocreatine - Lumos Pharma

Alternative Names: CincY; Cyclocreatine - Lumos Pharma; LUM-001 - Lumos Pharma; UNII-6732XGX1RK

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Cincinnati
  • Developer Lumos Pharma
  • Class Amino acids; Anti-ischaemics; Antineoplastics; Antivirals; Imidazolidines; Small molecules
  • Mechanism of Action Creatine replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked genetic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported X-linked creatine deficiency

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in X-linked-creatine-deficiency in USA (PO)
  • 18 Jun 2012 Lumos Pharma's cyclocreatine receives Orphan Drug status for X-linked-genetic-disorders in USA
  • 07 Feb 2012 Preclinical trials in X-linked creatine deficiency in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top